Cannabis (THC) for Chronic Pain
Delta-9-tetrahydrocannabinol, the primary psychoactive cannabinoid in Cannabis sativa, acting as a partial agonist at CB1 receptors; used medically for chronic pain, chemotherapy-induced nausea, appetite stimulation, and spasticity. Subject to legal restrictions varying by jurisdiction.
Cannabis (THC) for Chronic Pain
1 of 1 result reported a benefit, from 1 published study.
1 review of trials · the chart counts everything measured
- 1 reported a benefit
Colour keyReported a benefitNo clear benefitUnclearPossible harmAmber is for highlights, such as where the most research is. It never means a result was good.
- Pain severity and treatment responseReported a benefitmeasurement not reportedSynthetic high THC products may moderately improve pain severity and response versus placebo in 1740 people over 1 to 6 months.1 review of trials2022 study ↗
Side effects: measured in 3 results. 3 results reported more side effects than the comparison group.
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every result is listed below.
See every resultThe connection
Persistent pain lasting longer than 3 months. Can stem from injury, inflammation, or nervous system dysfunction.
Also known as: THC, Delta-9-tetrahydrocannabinol, Marijuana, Cannabis sativa
Cannabis (THC) × Chronic Pain: at a glance
Every published result for this pair, extracted and audited.
These charts count reported findings from published studies, grouped by reported benefit and study design. Study design is not a certainty grade.
Cannabis (THC) / Chronic Pain: reported findings; one study may contribute several findings.
What the evidence shows
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Findings (count) |
|---|---|
| Harm / risk | 3 |
| Benefit | 1 |
Study designs behind these findings
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Findings (count) |
|---|---|
| Systematic review | 4 |
- Studies
- 1
| Study | Outcome | Reported result | Uncertainty (as reported) | Study duration |
|---|---|---|---|---|
| Cannabis-Based Products for Chronic Pain : A Systematic Review. (PMID 35667066) | dizziness | Not reported | Not reported | 1 to 6 months |
| Cannabis-Based Products for Chronic Pain : A Systematic Review. (PMID 35667066) | pain severity and response | Not reported | Not reported | 1 to 6 months |
| Cannabis-Based Products for Chronic Pain : A Systematic Review. (PMID 35667066) | sedation | Not reported | Not reported | 1 to 6 months |
| Cannabis-Based Products for Chronic Pain : A Systematic Review. (PMID 35667066) | study withdrawal due to adverse events | Not reported | Not reported | 1 to 6 months |
Study results, as reported by the publications
Every measured outcome, one row per finding - numbers exactly as reported. Units are preserved where supplied; missing units are not inferred.
| Study and type | Reported sample and duration | Outcome measured | Reported result | What studies found |
|---|---|---|---|---|
| PMID 35667066 2022 Systematic review | Sample (as reported): 1740Duration: 1 to 6 months | dizziness | Not reported | Harm / risk |
| PMID 35667066 2022 Systematic review | Sample (as reported): 1740Duration: 1 to 6 months | pain severity and response | Not reported | Benefit |
| PMID 35667066 2022 Systematic review | Sample (as reported): 1740Duration: 1 to 6 months | sedation | Not reported | Harm / risk |
| PMID 35667066 2022 Systematic review | Sample (as reported): 1740Duration: 1 to 6 months | study withdrawal due to adverse events | Not reported | Harm / risk |
Cannabis (THC) × Chronic Pain: the evidence base
Hand-selected PubMed studies, linked to the originals.
Ordered by strength of evidence, then result direction.
01Cannabis-Based Products for Chronic Pain : An Updated Systematic ReviewChou R, et al. · Annals of internal medicine · 2026PMID 41429020 ↗02The effects of oral cannabidiol supplementation on blood pressure in adults: a systematic review of randomised controlled trialsRoberts A, et al. · Journal of cannabis research · 2026PMID 42321899 ↗03Effectiveness of Cannabidiol to Manage Chronic Pain: A Systematic ReviewMohammed SYM, et al. · Pain management nursing : official journal of the American Society of Pain Management Nurses · 2024PMID 37953193 ↗04Cannabis and Cannabinoids in Adults With Cancer: ASCO GuidelineBraun IM, et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024PMID 38478773 ↗05Evidence-Based Treatment of Pain in Chemotherapy-Induced Peripheral NeuropathyD'Souza RS, et al. · Current pain and headache reports · 2023PMID 37058254 ↗06Cannabis-based medicines and medical cannabis for adults with cancer painHäuser W, et al. · The Cochrane database of systematic reviews · 2023PMID 37283486 ↗Community experiences
Contributors volunteered; this does not establish treatment effectiveness or population incidence.
Reported changes
No publishable community breakdown is available. This does not establish that no reports exist.